반응식
[N:1](=[C:3]([C:9]1[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=1)[CH2:4][CH2:5][C:6]([OH:8])=O)[OH:2].Cl.Cl.[CH:17]([N:20]1[CH2:25][CH2:24][NH:23][CH2:22][CH2:21]1)([CH3:19])[CH3:18]>>[CH:17]([N:20]1[CH2:25][CH2:24][N:23]([C:6](=[O:8])[CH2:5][CH2:4][C:3]([C:9]2[CH:14]=[CH:13][CH:12]=[CH:11][CH:10]=2)=[N:1][OH:2])[CH2:22][CH2:21]1)([CH3:19])[CH3:18]참가 물질
3
실험 절차
Using coupling method A, 4-hydroximino-4-phenylbutyric acid (500 mg, 2.6 mmol) and 1-isopropylpiperazine dihydrochloride (521 mg, 2.6 mmol) afforded, after purification (SiO2: 10% isopropylamine in EtOAc), 730 mg (89%) of the title compound.
후처리
- customafforded
- customafter purification (SiO2: 10% isopropylamine in EtOAc), 730 mg (89%) of the title compound
출처 및 근거
- ORD 기록
- ord-5ee8ce0057a141558d8a7a003d34a7f0
- 출처 데이터셋
- uspto-grants-2008_09
- 특허 번호
- US07427632B2
연결된 노트
불러오는 중…